NCT05671497CompletedPhase 2/3
The Effect of Cilostazol on Rheumatoid Arthritis Patients
Evaluation of the Effect of Cilostazol on the Clinical Outcomes of Rheumatoid Arthritis Patients
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
The goal of this study is to evaluate the effect of cilostazol on Rheumatoid Arthritis patients. It aims to answer the questions of : 1. Will Cilostazol improve the disease severity and quality of life in Rheumatoid arthritis patients? 2. Will Cilostazol decrease the oxidative stress, inflammation and endothelial dysfunction in Rheumatoid arthritis patients? Participants will be randomized into two arms either treatment or control the treatment group will be asked to take Cilostazol 100 mg twice daily in addition to the usual DMARD (Methotrexate , Sulfasalazine , Hydroxychloroquine or Leflunomide), while the control group will be taking the usual DMARDs only. Patients in both arms will be followed-up every 2 weeks through out the 6-month duration of the study.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 70 (actual)
- First submitted
- 14 Dec 2022
- Start date
- 1 Nov 2022
- Primary completion date
- 1 Oct 2024
- Lead sponsor
- Ain Shams University
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT05671497
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 70
- From 1 Nov 2022 to the primary completion date, 1 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving any other antiplatelet or anticoagulant
Other illness
- Hypersensitivity to cilostazol.
- Heart failure.
- Patients with renal impairment (CrCl\<60 mL/min).
Lab values
- Patients with liver impairment (ALT or AST \> 3\* ULN).
Other
- Pregnant and lactating women.
Who the study is looking for
- Adult patients. (\>18 years old).
- Moderate to high disease activity (DAS28-CRP\>3.2).
- Patients receiving stable cDMARD regimen for at least 3 months before inclusion in the study.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Al Zahraa hospital Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.